2024-511516-24-00Not yet recruitingPhase 1
A phase I, open-label, dose-escalation, safety, pharmacokinetic/-dynamic and clinical activity study of p38α inhibitor Skepinone-L to enhance therapeutic efficacy of Sorafenib in advanced hepatocellular carcinomas of non-viral origin
Source: EU CTIS (euclinicaltrials.eu) · Last updated 29 Sept 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 30 Jul 2026
- Start date
- 1 Dec 2026
- Lead sponsor
- Universitaetsklinikum Tuebingen AöR
- Diseases
- Liver and biliary tract cancer
- EU CT number
- 2024-511516-24-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Tuebingen AöR | Tuebingen | Germany | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.